NextCure 10-Q: $8.7M Cash, Going Concern Warning and Nasdaq Equity Deficiency Ahead of Dec 9 Merger Vote
NXTC has more than doubled off its 52-week low of $1.55.
Summary
NextCure ended Q3 with $8.7 million of cash and a $6.8 million quarterly loss, disclosed substantial going-concern doubt and a Nasdaq equity deficiency, and is now entirely dependent on the December 9, 2026 vote to merge with Avere.
Key Events · Earnings and Guidance · NXTC
-
Q3 Loss Narrows to $6.8M
Net loss was $6.8 million for the three months ended September 30, 2026 versus $8.6 million a year earlier, as R&D fell to $4.5 million from $6.1 million after restructuring; nine-month net loss was $31.5 million versus $46.4 million.
-
Cash Falls to $8.7M, Going Concern
Cash and cash equivalents were $8.7 million at September 30, 2026, down from $25,982 thousand at December 31, 2025 after $35.2 million of operating cash use; management states substantial doubt about the ability to continue as a going concern, with runway only into early 2027.
-
Nasdaq Equity Deficiency Disclosed
Stockholders' equity of $5.5 million at September 30, 2026 is below Nasdaq's $10.0 million minimum equity standard for continued listing; the company may need a compliance plan and could face delisting.
-
Merger Vote Set for December 9
The S-4 was declared effective November 6, 2026 and the special meeting is scheduled for December 9, 2026; the Avere merger carries roughly $820 million of committed financing, of which about $266 million is satisfied by cancelling Avere convertible notes rather than new cash.
Analysis · NXTC · Life Sciences
NextCure's quarterly report makes explicit what the merger is really about: with $8.7 million of cash and $35.2 million burned in nine months, management states substantial doubt about the company's ability to continue as a going concern, with runway only into early 2027. The filing also newly discloses that stockholders' equity of $5.5 million sits below Nasdaq's $10.0 million continued-listing threshold, adding a delisting risk on top of the going-concern doubt. Everything now hinges on the December 9, 2026 shareholder vote on the Avere reverse merger, which brings roughly $820 million of committed financing (about $266 million of it from cancelling Avere convertible notes rather than new cash) — capital that is unavailable to NextCure if the deal fails. If the merger is not approved, the filing says the board may pursue dissolution and liquidation, in which case stockholders would likely recover little or nothing.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $5.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.